BMRA — BIOMERICA INC

Nasdaq · Health Care · Life Sciences Tools & Services · CIK 73290 ·
Last close
$2.47
Market Cap
$7.63M
52W High
$2.49
52W Low
$1.87
ADV30
18,049
Next earnings
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. The company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the inFoods platform in Canada. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Feb 2026 987,000 -44,000 -1,298,000 -1,312,000 4,878,000 1,336,000 1,561,000
Nov 2025 1,210,000 51,000 -1,373,000 -1,320,000 6,034,000 2,543,000 1,599,000
Aug 2025 1,380,000 424,000 -1,118,000 2,000 6,854,000 3,053,000 1,699,000
May 2025 749,000 -244,000 -1,564,000 -1,544,000 5,945,000 2,399,000 1,840,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-3,170,000
Investing CF
$-56,000
Financing CF
$1,458,000
CapEx
$-4,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.37
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-55,798,000
Inventory
$1,645,000
Receivables
$941,000
ST Investments
EBIT TTM
$-5,353,000
Pretax Income TTM
$-4,153,000
Interest Exp TTM
$6,000
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,327,000
EBITDA
$-5,268,000
Free Cash Flow
$-2,028,375
Enterprise Value
$6,551,770
Total Cash
$1,336,000
Total Debt
$193,000
Shares Out
3,090,269
Trailing EPS
$-1.63
Book Value
$1.09
ROE
-94.3%
ROA
-54.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
May 2025 5,311,000 -5,137,000 -4,973,000 5,945,000 1,840,000 -3,841,000
May 2024 5,415,000 -6,367,000 -5,978,000 9,254,000 2,663,000 -5,361,000
May 2023 5,339,000 -7,223,000 -7,140,000 14,454,000 2,730,000 -5,474,000
May 2022 18,871,000 -4,534,000 -4,531,000 11,374,000 3,049,000 -479,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.39

Peers — same industry

TickerNameMarket CapLastDaily %
BIAF bioAffinity Technologies, Inc. $7.48M $1.65
NOTV Inotiv, Inc. $9.30M $0.27
CDIO Cardio Diagnostics Holdings, Inc. $5.24M $1.77
BUDZ WEED, INC. $5.04M $0.03
ISPC iSpecimen Inc. $4.86M $3.38

News headlines (Yahoo Finance, 1h cache)

Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
2026-04-29 12:19 · Yahoo
Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
2026-04-16 12:19 · Yahoo
Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
2026-04-14 12:19 · Yahoo
Biomerica Reports Third Quarter Fiscal 2026 Financial Results
2026-04-13 22:57 · Yahoo
Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
2026-03-18 12:19 · Yahoo
Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
2026-03-05 13:19 · Yahoo
Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
2026-02-26 13:19 · Yahoo
Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution
2026-02-18 13:19 · Yahoo
Biomerica Reports Second Quarter Fiscal 2026 Financial Results
2026-01-14 22:17 · Yahoo
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
2025-12-23 13:19 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.